Dietary Treatments and New Therapeutic Perspective in GLUT1 Deficiency Syndrome

Part of the following topical collections:
  1. Topical Collection on Pediatric Neurology

Opinion statement

GLUT1 deficiency syndrome (GLUT1DS) results from impaired glucose transport into the brain: awareness of its wide phenotypic spectrum is a prerequisite in order to ensure an early diagnosis, treating the patients is the subsequent challenge to allow prompt compensation for the brain’s lack of fuel. The ketogenic diet (KD) plays a primary role in the treatment of GLUT1DS because it provides ketone bodies as an alternative source to meet the demands of energy of the brain. Therefore, we recommend early initiation of the KD based on the assumption that early diagnosis and treatment improves the long term neurological outcome: the classic KD (4:1 or 3:1) at the present time is the most proven and effective in GLUT1DS. A KD should be continued at least until adolescence, although there are reports of good tolerability even in adulthood, possibly with a less rigorous ratio; in our experience seizure and movement disorder control can be achieved by a 2:1 ketogenic ratio but the relationship between ketosis and neurodevelopmental outcome remains undetermined. Other types of KDs can, therefore, be considered. The Modified Atkins diet, for example, is also well tolerated and provides effective symptom control; furthermore, this diet has the advantage of being easy to prepare and more palatable, which are important requirements for good compliance. Nevertheless, about 20 % of these patients have compliance trouble or the same diet loses its effectiveness over time; for these reasons, new therapeutic strategies are currently under investigation but further studies on pathophysiological mechanisms and potential effects of novel “diets” or “therapies” are needed for this new pathology.


GLUT1 deficiency syndrome SLC2A1 gene Epilepsy Movement disorder Mental retardation Ketogenic diet Modified Atkins diet Low glycemic index treatment Triheptanoin Antiepileptic drugs 

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Vannucci SJ, Maher F, Simpson IA. Glucose transporter proteins in brain: delivery of glucose to neurons and glia. Glia. 1997;21:2–21.PubMedCrossRefGoogle Scholar
  2. 2.
    De Vivo DC, Trifiletti RR, Jacobson RI, Ronen GM, Behman RA, Harik SI. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med. 1991;325:703–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Wang D, Pascual JM, Yang H, Engelstad K, Jhung S, Sun RP, et al. Glut-1 deficiency syndrome: clinical, genetic, and therapeutic aspects. Ann Neurol. 2005;57:111–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Brockmann K. The expanding phenotype of GLUT1-deficiency syndrome. Brain and Development. 2009;31:545–52.PubMedCrossRefGoogle Scholar
  5. 5.
    Leen WG, Klepper J, Verbeek MM, Leferink M, Hofste T, van Engelen BG, et al. Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain. 2010;133(Pt 3):655–70.PubMedCrossRefGoogle Scholar
  6. 6.
    Suls A, Dedeken P, Goffin K, Van Esch H, Dupont P, Cassiman D, et al. Paroxysmal exerciseinduced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain. 2008;131:1831–44.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Pons R, Collins A, Rotstein M, Engelstad K, De Vivo DC. The spectrum of movement disorders in Glut-1 deficiency. Mov Disord. 2010;25:275–81.PubMedCrossRefGoogle Scholar
  8. 8.
    Klepper J, Scheffer H, Elsaid MF, Jamsteeg E-J, Leferink M, Ben-Omran T. Autosomal recessive inheritance of GLUT1 deficiency syndrome. Neuropediatrics. 2009;40:207–10.PubMedCrossRefGoogle Scholar
  9. 9.
    Rotstein M, Engelstad K, Yang H, Wang D, Levy B, Chung WK, et al. Glut1 deficiency: inheritance pattern determined by haploinsufficiency. Ann Neurol. 2010;68:955–8.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.•
    De Giorgis V, Veggiotti P. GLUT1 deficiency syndrome 2013: current state of the art. Seizure. 2013;22(10):803–11. This recent review clearly details the different GLUT1DS phenotypes, highlights the latest diagnostic and therapeutic procedures and it provides a handy and useful diagnostic flow chart.PubMedCrossRefGoogle Scholar
  11. 11.
    Ramm-Pettersen A, Nakken KO, Skogseid IM, Randby H, Skei EB, Bindoff LA, et al. Good outcome in patients with early dietary treatment of GLUT-1 deficiency syndrome: results from a retrospective Norwegian study. Dev Med Child Neurol. 2013;55(5):440–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Gras D, Roze E, Caillet S, Méneret A, Doummar D, Billette de Villemeur T, et al. GLUT1 deficiency syndrome: an update. Rev Neurol (Paris). 2013 Nov 20.Google Scholar
  13. 13.
    Veggiotti P, Teutonico F, Alfei E, Nardocci N, Zorzi G, Tagliabue A, et al. Glucose transporter type 1 deficiency: ketogenic diet in three patients with atypical phenotype. Brain Dev. 2010;32:404–8.PubMedCrossRefGoogle Scholar
  14. 14.••
    Pong AW, Geary BR, Engelstad KM, Natarajan A, Yang H, De Vivo DC. Glucose transporter type I deficiency syndrome: epilepsy phenotypes and outcome. Epilepsia. 2012;53(9):503–10. This retrospective study details the epilepsy phenotypes and treatment response to the ketogenic diet and anticonvulsant mediations in 87 patients with Glut1DS.CrossRefGoogle Scholar
  15. 15.
    Klepper J, Scheffer H, Leiendecker B, Gertsen E, Binder S, Leferink M, et al. Seizure control and acceptance of the ketogenic diet in GLUT1 deficiency syndrome: a 2- to 5-year follow-up of 15 children enrolled prospectively. Neuropediatrics. 2005;36(5):302–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Tzadok M, Nissenkorn A, Porper K, Matot I, Marcu S, Anikster Y, et al. The many faces of glut1 deficiency syndrome. J Child Neurol. 2014;29(3):349–59. doi:10.1177/0883073812471718.PubMedCrossRefGoogle Scholar
  17. 17.•
    Klepper J, Leiendecker B. Glut1 deficiency syndrome and novel ketogenic diets. J Child Neurol. 2013;28(8):1045–8. It is a clear, concise and detailed paper on the current data on novel ketogenic diets and faces the implications on the use of these diets in regard to GLUT1DS.PubMedCrossRefGoogle Scholar
  18. 18.••
    Klepper J. GLUT1 deficiency syndrome in clinical practice. Epilepsy Res. 2012;100:272–7. This accurate and precise review is useful for a practical approach in the suspicion of GLUT1DS. It faces the complexity of symptoms’ recognition, the genetic heterogeneity and diagnostic difficulties about cut-offs for hypoglycorrhachia.PubMedCrossRefGoogle Scholar
  19. 19.
    Kim DW, Kang HC, Park JC, Kim HD. Benefits of the nonfasting ketogenic diet compared with the initial fasting ketogenic diet. Pediatrics. 2004;114:1627–30.PubMedCrossRefGoogle Scholar
  20. 20.
    Kossoff EH, McGrogan JR, Bluml RM. A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy. Epilepsia. 2006;47:421–4.PubMedCrossRefGoogle Scholar
  21. 21.•
    Kossoff EH, Cervenka MC, Henry BJ, Haney CA, Turner Z. A decade of the modified Atkins diet (2003–2013): results, insights, and future directions. Epilepsy Behav. 2013;29(3):437–42. This review discusses the past decade of experience with the modified Atkins diet with results demonstrating similar efficacy to the classical ketogenic diet and its tolerability.PubMedCrossRefGoogle Scholar
  22. 22.
    Haberlandt E, Karall D, Jud V, Baumgartner SS, Zotter S, Rostasy K, et al. Glucose transporter type 1 deficiency syndrome effectively treated with modified Atkins diet. Neuropediatrics. 2013 Jul 25.Google Scholar
  23. 23.
    Pfeifer HH, Thiele EA. Low-glycemic-index treatment: a liberalized ketogenic diet for treatment of intractable epilepsy. Neurology. 2005;5:1810–2.CrossRefGoogle Scholar
  24. 24.••
    Kossoff EH, Freeman JM, Turner Z, Rubenstein JE. Ketogenic diets: treatments for epilepsy and other disorders. 5th ed. New York NY: Demos Medical; 2011. Clear and complete overview on the ketogenic diets, with particular regard to the practical management in the different clinical pictures.Google Scholar
  25. 25.
    Yang H, Wang D, Engelstad K, Bagay L, Wei Y, Rotstein M, et al. Glut1 deficiency syndrome and erythrocyte glucose uptake assay. Ann Neurol. 2011;70(6):996–1005.PubMedCrossRefGoogle Scholar
  26. 26.
    Klepper J, Leiendecker B. GLUT1 deficiency syndrome – 2007 update. Dev Med Child Neurol. 2007;49:707–16.PubMedCrossRefGoogle Scholar
  27. 27.
    Weber YG, Storch A, Wuttke TV, Brockmann K, Kempfle J, Maljevic S, et al. GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Invest. 2008;118(6):2157–68.PubMedCentralPubMedGoogle Scholar
  28. 28.
    Urbizu A, Cuenca-Leon E, Raspall-Chaure M, Gratacòs M, Conill J, Redecillas S, et al. Paroxysmal exercise-induced dyskinesia, writer’s cramp, migraine with aura and absence epilepsy in twin brothers with a novel SLC2A1 missense mutation. J Neurol Sci. 2010;295:110–3.PubMedCrossRefGoogle Scholar
  29. 29.
    Friedman JR, Thiele EA, Wang D, Levine KB, Cloherty EK, Pfeifer HH. Atypical GLUT1 deficiency with prominent movement disorder responsive to ketogenic diet. Mov Disord. 2006;21(2):241–5.PubMedCrossRefGoogle Scholar
  30. 30.•
    Gramer G, Wolf NI, Vater D, Bast T, Santer R, Kamsteeg EJ, et al. Glucose transporter-1 (GLUT1) deficiency syndrome: diagnosis and treatment in late childhood. Neuropediatrics. 2012;43(3):168–71. This paper interestingly describes symptoms, diagnostic results, and effects of therapy in two GLUT1-DS patients aged 10 and 15 years.PubMedCrossRefGoogle Scholar
  31. 31.
    Ito S, Oguni H, Ito Y, Ishigaki K, Ohinata J, Osawa M. Modified Atkins diet therapy for a case with glucose transporter type 1 deficiency syndrome. Brain Dev. 2008;30:226–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Coman DJ, Sinclair KG, Burke CJ, Appleton DB, Pelekanos JT, O'Neil CM, et al. Seizures, ataxia, developmental delay and the general paediatrician: glucose transporter 1 deficiency syndrome. J Paediatr Child Health. 2006;42:263–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Ito Y, Oguni H, Ito S, Oguni M, Osawa M. A modified Atkins diet is promising as a treatment for glucose transporter type 1 deficiency syndrome. Dev Med Child Neurol. 2011;53(7):658–63.PubMedCrossRefGoogle Scholar
  34. 34.
    Kitamura Y, Okumura A, Hayashi M, Mori H, Takahashi S, Yanagihara K, et al. Oxidative stress markers and phosphorus magnetic resonance spectroscopy in a patient with GLUT1 deficiency treated with modified Atkins diet. Brain Dev. 2012;34(5):372–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Pearson TS, Akman C, Hinton VJ, Engelstad K, De Vivo DC. Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS). Curr Neurol Neurosci Rep. 2013;13(4):342.PubMedCrossRefGoogle Scholar
  36. 36.
    Klepper J, Fischbarg J, Vera JC, Wang D, De Vivo DC. GLUT1- deficiency: barbiturates potentiate haploinsufficiency in vitro. Pediatr Res. 1999;46(6):677–83.PubMedCrossRefGoogle Scholar
  37. 37.
    von Moers A, Brockmann K, Wang D, Korenke CG, Huppke P, De Vivo DC, et al. EEG features of glut-1 deficiency syndrome. Epilepsia. 2002;43(8):941–5.CrossRefGoogle Scholar
  38. 38.
    Cano A, Ticus I, Chabrol B. Glucose transporter type 1 (GLUT-1) deficiency. Rev Neurol (Paris). 2008;164(11):896–901.CrossRefGoogle Scholar
  39. 39.
    Verrotti A, D’Egidio C, Agostinelli S, Gobbi G. Glut1 deficiency: when to suspect and how to diagnose? Eur J Paediatr Neurol. 2012;16:3–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Anheim M, Maillart E, Vuillaumier-Barrot S, Flamand-Rouvière C, Pineau F, Ewenczyk C, et al. Excellent response to acetazolamide in a case of paroxysmal dyskinesias due to GLUT1-deficiency. J Neurol. 2011;258:316–7.PubMedCrossRefGoogle Scholar
  41. 41.
    De Vivo DC, Leary L, Wang D. Glucose transporter 1 deficiency syndrome and other glycolytic defects. J Child Neurol. 2002;17 Suppl 3:S15–23.Google Scholar
  42. 42.
    Mochel F, DeLonlay P, Touati G, Brunengraber H, Kinman RP, Rabier D, et al. Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy. Mol Genet Metab. 2005;84(4):305–12.PubMedCrossRefGoogle Scholar
  43. 43.
    Kinman RP, Kasumov T, Jobbins KA, Thomas KR, Adams JE, Brunengraber LN, et al. Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats. Am J Physiol Endocrinol Metab. 2006;291(4):E860–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Deng S, Zhang GF, Kasumov T, Roe CR, Brunengraber H. Interrelations between C4 ketogenesis, C5 ketogenesis, and anaplerosis in the perfused rat liver. J Biol Chem. 2009;284(41):27799–807.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Borges K, Sonnewald U. Triheptanoin–a medium chain triglyceride with odd chain fatty acids: a new anaplerotic anticonvulsant treatment? Epilepsy Res. 2012;100(3):239–44.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Willis S, Stoll J, Sweetman L, Borges K. Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models. Neurobiol Dis. 2010;40(3):565–72.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Thomas NK, Willis S, Sweetman L, Borges K. Triheptanoin in acute mouse seizure models. Epilepsy Res. 2012;99(3):312–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Kim TH, Borges K, Petrou S, Reid CA. Triheptanoin reduces seizure susceptibility in a syndrome-specific mouse model of generalized epilepsy. Epilepsy Res. 2013;103(1):101–5.PubMedCrossRefGoogle Scholar
  49. 49.•
    Veggiotti P, Burlina A, Coppola G, Cusmai R, De Giorgis V, Guerrini R, et al. The ketogenic diet for Dravet syndrome and other epileptic encephalopathies: an Italian consensus. Epilepsia. 2011;52 Suppl 2:83–9. This is an interesting review that provides a consensus statement regarding the clinical management, patient selection, counseling and follow-up of the ketogenic diet in the Italian experience.PubMedCrossRefGoogle Scholar
  50. 50.
    Chambon R, Vuillaumier-Barrot S, Seta N, Wagner S, Sarret C. Partial effectiveness of acetazolamide in a mild form of GLUT1 deficiency: a pediatric observation. Mov Disord. 2013;28(12):1749–51.PubMedCrossRefGoogle Scholar
  51. 51.
    Brockmann K. Towards a more palatable treatment for Glut1 deficiency syndrome. Dev Med Child Neurol. 2011;53(7):580–1.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Child Neurology and Psychiatry C. Mondino National Neurological InstitutePaviaItaly
  2. 2.Brain and Behaviour DepartmentUniversity of PaviaPaviaItaly

Personalised recommendations